

Revision date: 06-Mar-2015 Version: 2.0 Page 1 of 11

1. IDENTIFICATION OF THE SUBSTANCE/MIXTURE AND THE COMPANY/UNDERTAKING

Product Identifier

Material Name: AVINZA (Morphine Sulfate) Extended Release Capusles

Trade Name: AVINZA Chemical Family: Opiod

Relevant Identified Uses of the Substance or Mixture and Uses Advised Against

Intended Use: Pharmaceutical active used as opioid analgesic

Details of the Supplier of the Safety Data Sheet

Pfizer Inc Pfizer Pharmaceuticals Group 235 East 42nd Street New York, New York 10017 1-800-879-3477

Emergency telephone number:
CHEMTREC (24 hours): 1-800-424-9300
Contact E-Mail: pfizer-MSDS@pfizer.com

Pfizer Ltd Ramsgate Road Sandwich, Kent CT13 9NJ United Kingdom +00 44 (0)1304 616161

Emergency telephone number:

International CHEMTREC (24 hours): +1-703-527-3887

2. HAZARDS IDENTIFICATION

Classification of the Substance or Mixture GHS - Classification

Acute Oral Toxicity: Category 4 Germ Cell Mutagenicity: Category 2 Reproductive Toxicity: Category 1B

Effects on or via lactation

EU Classification:

EU Indication of danger: Harmful

Toxic to reproduction, Category 2

Mutagenic: Category 3

EU Risk Phrases:

R22 - Harmful if swallowed.

R61 - May cause harm to the unborn child. R64 - May cause harm to breastfed babies. R68 - Possible risk of irreversible effects.

Label Elements

Signal Word: Dange

Hazard Statements: H302 - Harmful if swallowed

H360D - May damage the unborn child H362 - May cause harm to breast-fed children H341 - Suspected of causing genetic defects

Material Name: AVINZA (Morphine Sulfate) Extended Release Page 2 of 11

Capusles

Revision date: 06-Mar-2015 Version: 2.0

Precautionary Statements: P202 - Do not handle until all safety precautions have been read and understood

P264 - Wash hands thoroughly after handling

P270 - Do not eat, drink or smoke when using this product P281 - Use personal protective equipment as required

P308 + P313 - IF exposed or concerned: Get medical attention/advice

P405 - Store locked up

P501 - Dispose of contents/container in accordance with all local and national regulations



Other Hazards
Australian Hazard Classification
(NOHSC):

No data available

Hazardous Substance. Non-Dangerous Goods.

Note:

This document has been prepared in accordance with standards for workplace safety, which requires the inclusion of all known hazards of the product or its ingredients regardless of the potential risk. The precautionary statements and warning included may not apply in all cases. Your needs may vary depending upon the potential for exposure in your workplace.

3. COMPOSITION / INFORMATION ON INGREDIENTS

Hazardous

Ingredient	CAS Number	EU ENEGO/EL INGO	EU Classification		%
		EINECS/ELINCS List		Classification	
Sodium lauryl sulfate	151-21-3	205-788-1	Not Listed	Not Listed	*
Sugar	57-50-1	200-334-9	Not Listed	Not Listed	*
Morphine Sulfate	64-31-3	200-582-8	Xn;R22	Acute Tox. 4,H302;	30, 45, 60,
			Muta.Cat.3;R68	Repr. 1B,H360D;	75, 90, or
			Repr.Cat.2;R61	Lact.,H362; Muta.	120mg***
			R64	2,H341	
Talc (non-asbestiform)	14807-96-6	238-877-9	Not Listed	Not Listed	*

Ingredient	CAS Number	EU EINECS/ELINCS List	EU Classification	GHS Classification	%
Ammonio methacrylate coploymer	33434-24-1	Not Listed	Not Listed	Not Listed	*
Povidone	9003-39-8	Not Listed	Not Listed	Not Listed	*
Fumaric acid	110-17-8	203-743-0	Xi; R36	Eye Irrit. 2A (H319)	*
Hard gelatin capsules	MIXTURE	Not Listed	Not Listed	Not Listed	*

Additional Information: * Proprietary

Ingredient(s) indicated as hazardous have been assessed under standards for workplace

In accordance with 29 CFR 1910.1200, the exact percentage composition of this mixture has been withheld as a trade secret.

^{***} per tablet/capsule/lozenge/suppository

Material Name: AVINZA (Morphine Sulfate) Extended Release Page 3 of 11

Capusles

Revision date: 06-Mar-2015 Version: 2.0

For the full text of the R phrases and CLP/GHS abbreviations mentioned in this Section, see Section 16

4. FIRST AID MEASURES

Description of First Aid Measures

Eye Contact: Flush with water while holding eyelids open for at least 15 minutes. Seek medical attention

immediately.

Skin Contact: Remove contaminated clothing. Flush area with large amounts of water. Use soap. Seek

medical attention.

Ingestion: Never give anything by mouth to an unconscious person. Wash out mouth with water. Do not

induce vomiting unless directed by medical personnel. Seek medical attention immediately.

Inhalation: Remove to fresh air and keep patient at rest. Seek medical attention immediately.

Most Important Symptoms and Effects, Both Acute and Delayed

Symptoms and Effects of For information on potential signs and symptoms of exposure, See Section 2 - Hazards

Exposure: Identification and/or Section 11 - Toxicological Information.

Medical Conditions None known

Aggravated by Exposure:

Indication of the Immediate Medical Attention and Special Treatment Needed

Notes to Physician:

5. FIRE FIGHTING MEASURES

Extinguishing Media: Extinguish fires with CO2, extinguishing powder, foam, or water.

Special Hazards Arising from the Substance or Mixture

Hazardous Combustion Emits toxic fumes of carbon monoxide, carbon dioxide, nitrogen oxides, sulfur oxides and other

Products: sulfur-containing compounds.

Fire / Explosion Hazards: Not applicable

Advice for Fire-Fighters

During all fire fighting activities, wear appropriate protective equipment, including self-contained breathing apparatus.

6. ACCIDENTAL RELEASE MEASURES

Personal Precautions, Protective Equipment and Emergency Procedures

Personnel involved in clean-up should wear appropriate personal protective equipment (see Section 8). Minimize exposure.

Environmental Precautions

Collecting:

Place waste in an appropriately labeled, sealed container for disposal. Care should be taken to avoid environmental release.

Methods and Material for Containment and Cleaning Up

Contain the source of spill if it is safe to do so. Collect spilled material by a method that Measures for Cleaning /

controls dust generation. A damp cloth or a filtered vacuum should be used to clean spills of

dry solids. Clean spill area thoroughly.

Additional Consideration for

Non-essential personnel should be evacuated from affected area. Report emergency Large Spills:

situations immediately. Clean up operations should only be undertaken by trained personnel.

Material Name: AVINZA (Morphine Sulfate) Extended Release Page 4 of 11

Capusles

Revision date: 06-Mar-2015 Version: 2.0

7. HANDLING AND STORAGE

Precautions for Safe Handling

Minimize dust generation and accumulation. If tablets or capsules are crushed and/or broken, avoid breathing dust and avoid contact with eyes, skin, and clothing. When handling, use appropriate personal protective equipment (see Section 8). Wash thoroughly after handling. Releases to the environment should be avoided. Review and implement appropriate technical and procedural waste water and waste disposal measures to prevent occupational exposure or environmental releases. Potential points of process emissions of this material to the atmosphere should be controlled with dust collectors, HEPA filtration systems or other equivalent controls.

Conditions for Safe Storage, Including any Incompatibilities

Store as directed by product packaging. Storage Conditions:

Pharmaceutical drug product Specific end use(s):

8. EXPOSURE CONTROLS / PERSONAL PROTECTION

Control Parameters

Refer to available public information for specific member state Occupational Exposure Limits.

Sodium lauryl sulfate

Pfizer OEL TWA-8 Hr: 0.3 mg/m³

Sugar

10 mg/m³ ACGIH Threshold Limit Value (TWA) 10 mg/m³ **Australia TWA** 10 mg/m³ **Belgium OEL - TWA Bulgaria OEL - TWA** 10.0 mg/m³ 10 mg/m³ Estonia OEL - TWA France OEL - TWA 10 mg/m³ Ireland OEL - TWAs 10 ma/m³ Latvia OEL - TWA 5 mg/m³ Lithuania OEL - TWA 10 mg/m³ **OSHA - Final PELS - TWAs:** 15 mg/m³ 10 mg/m³ Portugal OEL - TWA Slovakia OEL - TWA 6 ma/m³ Spain OEL - TWA 10 mg/m³

Talc (non-asbestiform)

ACGIH Threshold Limit Value (TWA) 2 mg/m^3 Australia TWA 2.5 mg/m³ **Austria OEL - MAKs** 2 mg/m³ **Belgium OEL - TWA** 2 mg/m³ 1.0 fiber/cm3 **Bulgaria OEL - TWA** 6.0 mg/m³ 3.0 mg/m³ 2.0 mg/m³ Czech Republic OEL - TWA **Denmark OEL - TWA** 0.3 fiber/cm3 **Finland OEL - TWA** 0.5 fiber/cm3 **Greece OEL - TWA** 10 mg/m³

2 mg/m³ 2 mg/m³ **Hungary OEL - TWA** Ireland OEL - TWAs 10 mg/m³ 0.8 mg/m^{3}

Material Name: AVINZA (Morphine Sulfate) Extended Release Page 5 of 11

Capusles

Revision date: 06-Mar-2015 Version: 2.0

8. EXPOSURE CONTROLS / PERSONAL PROTECTION

Lithuania OEL - TWA 2 mg/m³ 1 mg/m³ **Netherlands OEL - TWA** 0.25 mg/m³ 20 mppcf OSHA - Final PELs - Table Z-3 Mineral D: Poland OEL - TWA 4.0 mg/m³ 1.0 mg/m³ 2 mg/m³ Portugal OEL - TWA Romania OEL - TWA 2 mg/m³ 2 mg/m³ Slovakia OEL - TWA 10 mg/m³ 2 mg/m³ Slovenia OEL - TWA 2 mg/m^3 Spain OEL - TWA 2 mg/m^3 Sweden OEL - TWAs 1 mg/m^3 **Switzerland OEL -TWAs** 2 mg/m³

Morphine Sulfate

Pfizer Occupational Exposure OEB 3 (control exposure to the range of 10ug/m³ to < 100ug/m³)

Band (OEB):

Exposure Controls

Engineering Controls: Engineering controls should be used as the primary means to control exposures. General

room ventilation is adequate unless the process generates dust, mist or fumes. Keep airborne

contamination levels below the exposure limits listed above in this section.

Personal Protective Refer to applicable national standards and regulations in the selection and use of personal

protective equipment (PPE). **Equipment:**

Impervious gloves are recommended if skin contact with drug product is possible and for bulk Hands:

processing operations.

Wear safety glasses or goggles if eye contact is possible. Eyes:

Impervious protective clothing is recommended if skin contact with drug product is possible and Skin:

for bulk processing operations.

If airborne exposures are within or exceed the Occupational Exposure Band (OEB) range, wear Respiratory protection:

an appropriate respirator with a protection factor sufficient to control exposures to the bottom of

the OEB range.

9. PHYSICAL AND CHEMICAL PROPERTIES

Physical State: Capsule Color: Various According to

product specification

No data available. **Odor Threshold:** No data available. Odor:

Molecular Formula: Mixture **Molecular Weight:** Mixture

No data available **Solvent Solubility:** Water Solubility: No data available pH: No data available. **Melting/Freezing Point (°C):** No data available **Boiling Point (°C):** No data available.

Partition Coefficient: (Method, pH, Endpoint, Value)

Talc (non-asbestiform) No data available

Hard gelatin capsules

Material Name: AVINZA (Morphine Sulfate) Extended Release Page 6 of 11

Capusles

Revision date: 06-Mar-2015 Version: 2.0

9. PHYSICAL AND CHEMICAL PROPERTIES

No data available **Fumaric acid** No data available

Povidone

No data available
Morphine Sulfate
No data available
Sodium lauryl sulfate
No data available

Sugar

No data available

Decomposition Temperature (°C): No data available.

Evaporation Rate (Gram/s):

Vapor Pressure (kPa):

Vapor Density (g/ml):

Relative Density:

No data available

Flammablity:

Autoignition Temperature (Solid) (°C):No data availableFlammability (Solids):No data availableFlash Point (Liquid) (°C):No data availableUpper Explosive Limits (Liquid) (% by Vol.):No data availableLower Explosive Limits (Liquid) (% by Vol.):No data available

10. STABILITY AND REACTIVITY

Reactivity: No data available

Chemical Stability: Stable under normal conditions of use.

Possibility of Hazardous Reactions

Oxidizing Properties: No data available

Conditions to Avoid: Fine particles (such as dust and mists) may fuel fires/explosions. **Incompatible Materials:** As a precautionary measure, keep away from strong oxidizers

Hazardous Decomposition No data available

Products:

11. TOXICOLOGICAL INFORMATION

Information on Toxicological Effects

General Information: The information included in this section describes the potential hazards of the individual

ingredients.

Short Term: Dust may cause irritation if tablets are crushed or broken

Long Term: Repeat-dose studies in animals have shown a potential to cause adverse effects on the

developing fetus.

Known Clinical Effects: Ingestion of this material may cause effects similar to those seen in clinical use including dry

mouth, drowsiness, headache, dizziness, nausea, vomiting, weakness, anxiety, blurred vision and dilated pupils. Cases of overdosage may also lead to respiratory depression, hypotension,

coma, convulsions, cardiac arrhythmia, and tachycardia.

Acute Toxicity: (Species, Route, End Point, Dose)

Material Name: AVINZA (Morphine Sulfate) Extended Release Page 7 of 11

Capusles

Revision date: 06-Mar-2015 Version: 2.0

11. TOXICOLOGICAL INFORMATION

Talc (non-asbestiform)

Rat Oral LD50 > 1600 mg/kg

Povidone

Rat Oral LD50 100 g/kg

Morphine Sulfate

Rat Oral LD50 461 mg/kg

Rat Para-periosteal LD50 70mg/kg
Rat Intraperitoneal LD50 235mg/kg

Mouse Oral LD50 600mg/kg Mouse Intravenous LD50 156mg/kg

Sodium lauryl sulfate

Rat Oral LD50 1288 mg/kg

Sugar

Rat Oral LD50 29700 mg/kg Mouse Oral LD50 14000mg/kg

Irritation / Sensitization: (Study Type, Species, Severity)

Fumaric acid

Eye Irritation Rabbit Moderate Skin Irritation Rabbit Mild

Sodium lauryl sulfate

Eye Irritation Rabbit Moderate
Skin Irritation Rabbit Mild Moderate
Skin Sensitization - GPMT Guinea Pig Negative
Skin Sensitization - LLNA Mouse Negative

Repeated Dose Toxicity: (Duration, Species, Route, Dose, End Point, Target Organ)

Morphine Sulfate

18 Week(s) Rat Oral60 g/kg LOAEL Lungs
15 Day(s) Rat Subcutaneous 3144 mg/kg LOAEL Kidney, Ureter, Bladder
9 Week(s) Rat Subcutaneous 3150 mg/kg LOAEL

Reproduction & Developmental Toxicity: (Study Type, Species, Route, Dose, End Point, Effect(s))

Morphine Sulfate

Embryo / Fetal Development Mouse Subcutaneous 0.15 mg/kg LOAEL Teratogenic 35 mg/kg Embryo / Fetal Development Hamster Subcutaneous LOAEL Teratogenic Embryo / Fetal Development Mouse Oral 200 mg/kg LOAEL Teratogenic Embryo / Fetal Development Rat Subcutaneous 35 mg/kg LOAEL Fetotoxicity

Genetic Toxicity: (Study Type, Cell Type/Organism, Result)

Morphine Sulfate

PZ01563

Material Name: AVINZA (Morphine Sulfate) Extended Release Page 8 of 11

Capusles

Revision date: 06-Mar-2015 Version: 2.0

11. TOXICOLOGICAL INFORMATION

In Vivo Micronucleus Mouse Positive

In Vivo Chromosome Aberration Mouse Lymphocytes Positive In Vitro Direct DNA Damage Human Lymphocytes Positive

In Vitro Chromosome Aberration Mouse Negative Dominant Lethal Assay Drosophila Negative

Sodium lauryl sulfate

Bacterial Mutagenicity (Ames) Salmonella Negative

Carcinogen Status: None of the components of this formulation are listed as a carcinogen by IARC, NTP or OSHA.

Talc (non-asbestiform)

IARC: Group 3 (Not Classifiable)

Povidone

IARC: Group 3 (Not Classifiable)

12. ECOLOGICAL INFORMATION

Environmental Overview: Environmental properties of the formulation have not been thoroughly investigated. Releases

to the environment should be avoided.

Toxicity:

Aquatic Toxicity: (Species, Method, End Point, Duration, Result)

Sodium lauryl sulfate

Oncorhynchus mykiss (Rainbow Trout) LC50 96 Hours 3.6 mg/L

Persistence and Degradability: No data available

Bio-accumulative Potential: No data available

Mobility in Soil: No data available

13. DISPOSAL CONSIDERATIONS

Waste Treatment Methods: Dispose of waste in accordance with all applicable laws and regulations. Member State

specific and Community specific provisions must be considered. Considering the relevant known environmental and human health hazards of the material, review and implement appropriate technical and procedural waste water and waste disposal measures to prevent occupational exposure and environmental release. It is recommended that waste minimization be practiced. The best available technology should be utilized to prevent environmental releases. This may include destructive techniques for waste and wastewater.

eleases. This may include destructive techniques for waste and wastew

14. TRANSPORT INFORMATION

The following refers to all modes of transportation unless specified below.

Not regulated for transport under USDOT, EUADR, IATA, or IMDG regulations.

Material Name: AVINZA (Morphine Sulfate) Extended Release Page 9 of 11

Capusles

Revision date: 06-Mar-2015 Version: 2.0

15. REGULATORY INFORMATION

Safety, Health and Environmental Regulations/Legislation Specific for the Substance or Mixture

Canada - WHMIS: Classifications WHMIS hazard class: D1b toxic materials D2a very toxic materials



EU EINECS/ELINCS List

CERCLA/SARA 313 Emission reporting Not Listed **California Proposition 65** Not Listed Inventory - United States TSCA - Sect. 8(b) Present Australia (AICS): Present **EU EINECS/ELINCS List** Not Listed

Sodium lauryl sulfate

CERCLA/SARA 313 Emission reporting Not Listed **California Proposition 65** Not Listed Inventory - United States TSCA - Sect. 8(b) Present Australia (AICS): Present Standard for the Uniform Scheduling Schedule 6 for Drugs and Poisons: 205-788-1

Povidone

CERCLA/SARA 313 Emission reporting Not Listed **California Proposition 65** Not Listed Inventory - United States TSCA - Sect. 8(b) Present Australia (AICS): Present **EU EINECS/ELINCS List** Not Listed

Fumaric acid

CERCLA/SARA 313 Emission reporting Not Listed **CERCLA/SARA Hazardous Substances** 5000 lb and their Reportable Quantities: 2270 kg **California Proposition 65** Not Listed Inventory - United States TSCA - Sect. 8(b) Present

Material Name: AVINZA (Morphine Sulfate) Extended Release Page 10 of 11

Capusles

Revision date: 06-Mar-2015 Version: 2.0

15. REGULATORY INFORMATION

Australia (AICS): Present EU EINECS/ELINCS List 203-743-0

Sugar

CERCLA/SARA 313 Emission reporting

California Proposition 65

Inventory - United States TSCA - Sect. 8(b)

Australia (AICS):

REACH - Annex IV - Exemptions from the

Present

Present

obligations of Register:

EU EINECS/ELINCS List 200-334-9

Hard gelatin capsules

CERCLA/SARA 313 Emission reporting

California Proposition 65

EU EINECS/ELINCS List

Not Listed

Not Listed

Morphine Sulfate

CERCLA/SARA 313 Emission reporting

California Proposition 65

U.S. Drug Enforcement Administration:

Australia (AICS):

Present

EU EINECS/ELINCS List

Not Listed

Schedule II

200-582-8

Talc (non-asbestiform)

CERCLA/SARA 313 Emission reporting

California Proposition 65

Inventory - United States TSCA - Sect. 8(b)

Australia (AICS):

Present

EU EINECS/ELINCS List

Not Listed

Present

238-877-9

Additional Information: U.S. Drug Enforcement Agency Controlled Drug Substance, Schedule II

16. OTHER INFORMATION

Text of R phrases and GHS Classification abbreviations mentioned in Section 3

Acute toxicity, oral-Cat.4; H302 - Harmful if swallowed

Reproductive toxicity-Cat.1B; H360D - May damage the unborn child

Reproductive toxicity, effects on or via lactation; H362 - May cause harm to breast-fed children

Germ cell mutagenicity-Cat.2; H341 - Suspected of causing genetic defects

Toxic to Reproduction: Category 2

Xn - Harmful

Mutagenic: Category 3

R22 - Harmful if swallowed.

R61 - May cause harm to the unborn child.

R64 - May cause harm to breastfed babies.

R68 - Possible risks of irreversible effects.

Data Sources: Safety data sheets for individual ingredients. Publicly available toxicity information. Pfizer

proprietary drug development information.

Material Name: AVINZA (Morphine Sulfate) Extended Release Page 11 of 11

Capusles

Prepared by:

Revision date: 06-Mar-2015 Version: 2.0

Reasons for Revision: Updated Section 2 - Hazard Identification. Updated Section 3 - Composition / Information on

Ingredients. Updated Section 7 - Handling and Storage. Updated Section 12 - Ecological Information. Updated Section 11 - Toxicology Information. Updated Section 1 - Identification of the Substance/Preparation and the Company/Undertaking. Updated Section 16 - Other

Information.

Revision date: 06-Mar-2015

Product Stewardship Hazard Communication
Pfizer Global Environment, Health, and Safety Operations

Pfizer Inc believes that the information contained in this Material Safety Data Sheet is accurate, and while it is provided in good faith, it is without warranty of any kind, expressed or implied. If data for a hazard are not included in this document there is no known information at this time.

End of Safety Data Sheet
